Eksigent Technologies has announced that it will be stepping up its manufacturing capabilities by 40%, as well as expanding the company?s servicing capabilities, to meet demand for its HPLC products.
Eksigent Technologies has announced that it will be stepping up its manufacturing capabilities by 40%, as well as expanding the company’s servicing capabilities, to meet demand for its HPLC products.
"The need for this increase in product build capability is being driven by higher than expected customer demand for both our cHiPLC-nanoflex for proteomics, introduced in February of this year, and our ExpressHT-Ultra HPLC system for ADME-Tox and DMPK studies, introduced last fall," said David Neyer, vice president and co-founder of the company, in a statement.
The cHiPLC-nanoflex system is a docking station for up to three microfluidic chips that contain nanoLC or trap columns. The ExpressHT-Ultra HPLC system provides small molecule analysis for LC–MS studies of pharmacokinetics and drug metabolism.
The company is also recruiting additional field service personnel to provide maintenance for the growing number of customer installations. The money for the extra staff, tools and equipment was approved by the company’s board of directors last month.
For more on the company visit www.eksigent.com
Traditional Chinese Medicine’s Effects on Liver Cancer Measured Using New UHPLC–QTOF-MS System
April 22nd 2024Scientists from Anhui University of Chinese Medicine in Hefei, China recently investigated the mechanisms behind what makes huachansu tablets, a type of traditional Chinese medicine (TCM), effective against liver cancer.